AGP Picks
View all

Top 9 Retatrutide OEM service companies ranked for 2026 sourcing needs

an hour ago
Top 9 Retatrutide OEM service companies ranked for 2026 sourcing needs
By AI, Created 22:48 UTC, Nov 15, 2026, AGP -

A new sourcing-focused review ranks nine companies for Retatrutide buyers in 2026, weighing documentation quality, batch consistency, packaging, supply stability and custom manufacturing communication. The list matters because demand is rising ahead of Eli Lilly’s planned 2027 BLA submission, but buyers still need to verify lawful supply and product status before placing orders.

Why it matters: - Retatrutide demand is rising before any regulatory approval, so buyers are competing for supply routes that can document quality and continuity. - Procurement teams need more than a price quote. They need proof of identity, purity, batch consistency, packaging control and market-specific compliance. - The review is relevant to buyers sourcing research material, private-label presentation, GMP API or development-stage scale-up support.

What happened: - A sourcing-focused editorial ranked nine companies for Retatrutide OEM and related supply needs across direct OEM/ODM manufacturing, GMP API and CDMO supply, private-label lot supply, wholesale research material and development-stage scale-up. - The ranking placed Bachem first, followed by Xi’an Yihui Kangyuan Bio-technology Co., Ltd., Langfang Jiwei Medical Technology Co., Ltd. (Jiwei), PepNova, Pepti (PeptiGLP1), Ruite Peptide, Winhycare Pharma, SeqLine Bio and Lumirabio. - The review said the ranking was not an official market list, regulatory approval list or claim that any company can sell a commercial medicine. - The methodology weighed category relevance, OEM/ODM customization, analytical documentation, supply stability and export or regulatory support. - Missing public data was treated as not publicly verified, not as a negative score.

The details: - Retatrutide remains an investigational once-weekly triple hormone receptor agonist targeting GIP, GLP-1 and glucagon receptors, according to Eli Lilly. - Eli Lilly has said it plans to submit a Biologics License Application for Retatrutide to the FDA in the first quarter of 2027. - IQVIA forecasts the global obesity medicines market will reach $92 billion in 2026. - Eli Lilly reported that Retatrutide 12 mg achieved 20.8% average weight loss over 80 weeks in adults with type 2 diabetes and obesity in TRIUMPH-2. - Bachem was ranked first for regulatory-grade GMP peptide API and custom manufacturing, supported by large-scale GMP production capacity, multiple certified sites, strong regulatory credentials and batch-to-batch reproducibility. - Xi’an Yihui Kangyuan Bio-technology Co., Ltd. reports five peptide production lines, cGMP alignment for US, EU and China requirements, about 500 kg annual capacity and nearly 20 years of R&D experience. - Jiwei reports a 4,500 square meter factory, 97 employees, 15 engineers and 80% export share to North America, Europe, New Zealand, Singapore, India, Malaysia and Russia. - Jiwei’s OEM/ODM terms include logo and dose customization, monthly capacity of 50,000 pieces, MOQ from 50 boxes and lead time of about two weeks. - Jiwei says quality control includes 100% inspection before shipment and at least 99% purity testing. - Jiwei cites GMP certificate CN20180070 issued by the China Food and Drug Administration, valid to 2027, covering small volume parenteral solutions and lyophilized powder for injection. - PepNova reports in-house solid-phase synthesis, at least 99% purity, full-release QC using HPLC and MS, and supply from gram to kilogram scale. - Pepti (PeptiGLP1) operates its own Guangzhou facility and publishes lot-by-lot COA with HPLC purity and MS identity. - Pepti’s service scope includes raw peptide powder, OEM/private-label packaging and one-roof synthesis, purification, lyophilization and filling. - Ruite Peptide reports a GMP-certified workshop, COA, HPLC and MS documentation, more than 100 kg annual output and 7-15 day delivery. - Winhycare Pharma says it supplies peptide APIs including Retatrutide, Tirzepatide and Semaglutide to European, US and globally licensed manufacturers and provides a COA with every batch. - Winhycare’s semaglutide portfolio is supported by US-DMF Type II and CTD Module 3 documentation. - SeqLine Bio offers private-label OEM Retatrutide research peptide in 10 mg lots with HPLC purity of at least 98%, MS identity, lot number and test or retest dates. - SeqLine states delivery takes 7-15 business days after specification confirmation. - Lumirabio supports development, synthesis, purification, analysis and scale-up, and supplies raw material for Retatrutide. - Lumirabio says it has upcoming capability to deliver GMP-level materials for the GLP-1 set.

Between the lines: - The ranking suggests the market is splitting into different buyer lanes: regulated API supply, OEM packaging, research lots and development-stage support. - Documentation is becoming a competitive advantage. Lot-level HPLC, MS data, batch records and packaging control make supplier qualification easier. - Public product listings do not prove manufacturing authorization. Buyers still need to verify Retatrutide-specific GMP status, certificate scope and destination-market compliance. - The strongest fit depends on the project stage. A research lot buyer needs different evidence than a buyer planning commercial or clinical continuity. - The review also shows that low MOQ and fast lead time can matter as much as scale for smaller OEM orders.

What's next: - Buyers should request controlled samples with a written documentation checklist before committing to long-term supply. - The next review step should be batch verification, including COA, HPLC method, MS identity, batch number, test and retest dates and packaging specification. - Supply continuity checks should cover monthly capacity, MOQ, lead time and after-sales response before any purchase agreement is signed. - Retatrutide sourcing is likely to remain documentation-led through 2026 and into the 2027 filing window.

The bottom line: - For Retatrutide OEM buyers, the best supplier is not the one with the loudest marketing. It is the one that can prove quality, continuity and market-fit with documents buyers can verify.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Journal of Business News

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Journal of Business News

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.